Pharmaceutical

EMA backs Wegovy cardiovascular label update as Novo seeks EU coverage

The EMA recommended a label update that allows the drug to be used to reduce cardiovascular risk.

Jul 28, 2024 - 04:00
EMA backs Wegovy cardiovascular label update as Novo seeks EU coverage
The EMA recommended a label update that allows the drug to be used to reduce cardiovascular risk.
Read the original article

Tags:

Previous Article

FDA committee proposes overhaul of perioperative lung cancer trials 

Next Article

FDA approves Sun Pharma’s JAK inhibitor for alopecia

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

US FDA approves Daiichi Sankyo’s acute myeloid leukaemia treatment

US FDA approves Daiichi Sankyo’s acute myeloid leukaemi...

Jul 21, 2023

Plus Therapeutics and PPS expand partnership for cGMP drug production

Plus Therapeutics and PPS expand partnership for cGMP d...

May 2, 2023

Polio transmission was supposed to end by 2023. A new report explains why it won’t.

Polio transmission was supposed to end by 2023. A new r...

Sep 16, 2023